Streptococcus pneumoniae capsular polysaccharides (serotypes 1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F) (PnPS)

Streptococcus pneumoniae capsular polysaccharides (PnPS) are complex carbohydrate polymers that form the outermost layer of the bacterium, serving as its primary virulence factor [1]. These polysaccharides are essential for the pathogen's survival within the host, as they provide a physical barrier that inhibits opsonization by complement proteins and subsequent phagocytosis by host immune cells [2]. There are over 100 distinct serotypes of S. pneumoniae, each defined by a unique polysaccharide structure that determines its immunogenicity and prevalence in disease [3]. The specific 22 serotypes listed (1, 2, 3, 4, 5, 6B, 7F, 8, 9N, 9V, 10A, 11A, 12F, 14, 15B, 17F, 18C, 19F, 19A, 20, 22F, 23F) are major contributors to invasive pneumococcal disease, including pneumonia, meningitis, and sepsis [4]. In a therapeutic context, these polysaccharides are used as antigens in vaccines to stimulate the production of type-specific antibodies [5]. These antibodies bind to the capsule, facilitating bacterial clearance through opsonophagocytosis, thereby providing protection against infection by the corresponding serotypes [6]. Vaccination targeting these polysaccharides has significantly reduced the global burden of pneumococcal disease, although serotype replacement remains a challenge [2]. Modern conjugate vaccines link these polysaccharides to carrier proteins to enhance the immune response, particularly in young children [1].

Other names

Pneumococcal capsular polysaccharidesS. pneumoniae surface polysaccharidesPneumococcal antigensCPSCapsular polysaccharide

Induction of serotype-specific humoral immunity through the production of opsonizing IgG antibodies that facilitate phagocytosis and clearance of the bacteria.